Boryung secures exclusive rights for blood cancer drug
Boryung secured exclusive rights for blood cancer drug Xpovio from Antengene. The oral medication targets multiple myeloma and diffuse large B-cell lymphoma, expanding Boryung's blood cancer portfolio to 8 drugs.
Boryung executive Lee Keun-jae sold 7,000 shares on February 10, 2026, reducing his holdings from 8,824 to 1,824 shares. Boryung's stock closed at 10,680 won on February 19, up 12.90%.
Boryung is conducting open recruitment for the first half of 2026, accepting applications until February 22nd for new and experienced positions across various departments.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.